Management Strategies and Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus Native Vertebral Osteomyelitis: A Systematic Review and Meta-Analysis.

Authors

Farzad Pourghazi, Seyed Mohammad Amin Alavi, Georges Baaklini, Ahmad Nassr, Brett A Freedman, Takahiro Matsuo, Aaron J Tande, Elie F Berbari

Published in

The spine journal : official journal of the North American Spine Society. Oct 18, 2026. Epub Oct 18, 2026.

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of native vertebral osteomyelitis (NVO) and is associated with persistent infection, complications, prolonged hospitalization, and increased mortality.
We conducted this systematic review and meta-analysis to evaluate the antimicrobial and surgical approaches used for MRSA NVO and their associated clinical outcomes.
Systematic review and meta-analysis.
A systematic literature search of MEDLINE, Scopus, and Web of Science was conducted on November 27, 2025. Studies were eligible if they included adults with MRSA NVO, evaluated medical or surgical treatment strategies, reported clinical outcomes, and included at least five patients. Two reviewers independently screened studies and extracted data. Risk of bias was assessed using the Newcastle-Ottawa Scale and the Murad et al. tool. Random-effects models were used to pool proportions of treatment success, reinfection, and mortality.
Thirty studies including 677 patients were included. Treatment strategies were heterogeneous and included prolonged anti-MRSA antimicrobial therapy and surgical approaches ranging from debridement and drainage to decompression and spinal stabilization or fusion. Vancomycin-based regimens were the most frequently reported antimicrobial strategy. Among studies reporting treatment duration, intravenous therapy commonly ranged from 4 to 8 weeks, with some patients receiving oral step-down or suppressive therapy. The pooled treatment success rate was 84.9% (95% CI, 76.7%-90.7%), pooled reinfection rate was 15.3% (95% CI, 9.5%-23.6%), and pooled mortality rate was 3.1% (95% CI, 0.8%-10.8%). Subgroup analyses were not feasible because treatment-specific data were limited and inconsistently reported.
Management of MRSA NVO varied substantially across studies, with vancomycin-based antimicrobial therapy and diverse surgical strategies commonly reported. Pooled outcomes showed high treatment success with lower rates of reinfection and mortality. The substantial clinical and methodological heterogeneity of the available evidence highlights the need for prospective studies with standardized treatment and outcome reporting.

PMID:
42893772
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.